We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

24 hedge funds and large institutions have $6.26M invested in CASI Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

14.41% more ownership

Funds ownership: 1.67% → 16.08% (+14%)

45% less funds holding

Funds holding: 44 → 24 (-20)

55% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 11

67% less capital invested

Capital invested by funds: $18.9M → $6.26M (-$12.6M)

95% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 21

Holders
24
Holders Change
-20
Holders Change %
-45.45%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
11
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
B
Bailard
California
+$126K
2
CS
Credit Suisse
Switzerland
+$12.2K
3
TRCT
Tower Research Capital (TRC)
New York
+$8.03K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.73K
5
Northern Trust
Northern Trust
Illinois
+$691

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$315K
2
Millennium Management
Millennium Management
New York
-$156K
3
Renaissance Technologies
Renaissance Technologies
New York
-$126K
4
Citadel Advisors
Citadel Advisors
Florida
-$124K
5
BlackRock
BlackRock
New York
-$119K

CASI Hedge Fund Activity: Q2 2022 in Review

24 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2022, worth a combined $6.26M — down 67% from $18.9M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CASI and 1 opened new positions — a net loss of 20 holders — while 11 trimmed existing stakes and 5 added.

The largest buyer was Bailard, adding an estimated $126K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $315K sold.

  • 24 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2022, down from 44 in Q1 2022.
  • Funds reported $6.26M of CASI Pharmaceuticals stock for Q2 2022, down 67% quarter-over-quarter.
  • 1 fund opened new CASI Pharmaceuticals positions in Q2 2022 and 21 closed out, a net change of -20 holders.
  • The largest CASI Pharmaceuticals buyer in Q2 2022 was Bailard, an estimated $126K added.
  • The largest CASI Pharmaceuticals seller in Q2 2022 was Susquehanna International Group, an estimated $315K sold.

Based on aggregated 13F filings for Q2 2022.